Keyphrases
Clinical Trials
82%
Patient Outcomes
69%
Core Outcome Set
62%
Regorafenib
62%
Risk Outcomes
62%
Risk-benefit
62%
Patient Benefit
62%
Drug Development
62%
Patient Risk
62%
Reporting Guidelines
31%
Stroke Trials
31%
Web-based Survey
31%
Lung Cancer
31%
Clinical Perspective
31%
Family Medicine
31%
Consolidated Standards of Reporting Trials (CONSORT)
22%
Drug Manufacturer
21%
Objective Response Rate
16%
Colorectal Cancer
15%
Overall Survival
15%
Tolerability
10%
In Cancer
10%
New Indication
10%
Pooled Analysis
10%
PubMed
10%
Novel Chemotherapy
10%
Drug Efficacy
10%
Median Progression-free Survival
10%
Adverse Event Rates
10%
Oncologic
10%
Solid Cancer
10%
Cochrane
10%
Embase
10%
Repurposing
10%
Cumulative Risk
10%
Response Rate
10%
STROBE Guidelines
8%
Clinical Trial Registry
8%
Reporting Quality
8%
PRISMA Guidelines
8%
Patient Demographics
7%
Trialists
6%
Trial Characteristics
6%
Randomized Controlled Trial
6%
Cancer Clinical Trials
6%
Impact-based
6%
Single-arm Trial
6%
High-quality Research
6%
Risk Profile
6%
Core Outcome Measures
5%
Medicine and Dentistry
Clinical Trial
100%
Lung Cancer
62%
Family Practice
62%
Cross Sectional Study
62%
Systematic Review
39%
Apoplexy
31%
Outcome Assessment
11%
Randomized Controlled Trial
9%
Patient Care
8%
Cancer Research
7%
Quality of Life
7%
Prevalence
7%
Writing
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
77%
Regorafenib
62%
Drug Development
62%
Lung Cancer
31%
Observational Study
31%
Malignant Neoplasm
30%
Pharmaceutical Manufacturing
21%
Adverse Event
19%
Overall Survival
15%
Progression Free Survival
15%
Colorectal Carcinoma
15%
Chemotherapy
10%
Tolerability
10%
